{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:42:47Z","timestamp":1794512567591,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T00:00:00Z","timestamp":1567555200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T00:00:00Z","timestamp":1567555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004480","name":"Natural Science Foundation of Shanxi Province","doi-asserted-by":"publisher","award":["201701D121086"],"award-info":[{"award-number":["201701D121086"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12865-019-0305-0","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T09:05:49Z","timestamp":1567587949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17\/Treg cells in refractory SLE patients"],"prefix":"10.1186","volume":"20","author":[{"given":"Chunmiao","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihua","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingzhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liguang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5053-9651","authenticated-orcid":false,"given":"Junwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,4]]},"reference":[{"key":"305_CR1","doi-asserted-by":"publisher","first-page":"419029","DOI":"10.1155\/2014\/419029","volume":"2014","author":"A Mak","year":"2014","unstructured":"Mak A, Kow NY. The pathology of T cells in systemic lupus erythematosus. J Immunol Res. 2014;2014:419029.","journal-title":"J Immunol Res"},{"issue":"2","key":"305_CR2","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cyto.2014.12.027","volume":"72","author":"RM Talaat","year":"2015","unstructured":"Talaat RM, Mohamed SF, Bassyouni IH, Raouf AA. Th1\/Th2\/Th17\/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: correlation with disease activity. Cytokine. 2015;72(2):146\u201353.","journal-title":"Cytokine."},{"key":"305_CR3","doi-asserted-by":"publisher","first-page":"893","DOI":"10.5604\/17322693.1111127","volume":"68","author":"M Szmyrkakaczmarek","year":"2014","unstructured":"Szmyrkakaczmarek M, Kosmaczewska A, Ciszak L, Szteblich A, Wiland P. Peripheral blood Th17\/Treg imbalance in patients with low-active systemic lupus erythematosus. Postepy Hig Med Dosw. 2014;68:893\u20138.","journal-title":"Postepy Hig Med Dosw"},{"key":"305_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2015.01.001","volume":"58","author":"M Rosenzwajg","year":"2015","unstructured":"Rosenzwajg M, Churlaud G, Mallone R, Six A, D\u00e9rian N, Chaara W, Lorenzon R, Long SA, Buckner JH, Afonso G, et al. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. J Autoimmun. 2015;58:48\u201358.","journal-title":"J Autoimmun"},{"issue":"22","key":"305_CR5","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","volume":"365","author":"J Koreth","year":"2011","unstructured":"Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP 3rd, Armand P, Cutler C, Ho VT, Treister NS, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365(22):2055\u201366.","journal-title":"N Engl J Med"},{"issue":"2","key":"305_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12185-017-2386-y","volume":"107","author":"KI Matsuoka","year":"2018","unstructured":"Matsuoka KI. Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives. Int J Hematol. 2018;107(2):130\u20137.","journal-title":"Int J Hematol"},{"issue":"179","key":"305_CR7","doi-asserted-by":"publisher","first-page":"179ra43","DOI":"10.1126\/scitranslmed.3005265","volume":"5","author":"KI Matsuoka","year":"2013","unstructured":"Matsuoka KI, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, Murase K, Cutler C, Ho VT, Alyea EP, et al. Low-dose Interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013;5(179):179ra43.","journal-title":"Sci Transl Med"},{"issue":"7","key":"305_CR8","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1001\/jamadermatol.2014.504","volume":"150","author":"E Castela","year":"2014","unstructured":"Castela E, Le Duff F, Butori C, Ticchioni M, Hofman P, Bahadoran P, Lacour JP, Passeron T. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol. 2014;150(7):748\u201351.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"305_CR9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.clim.2013.01.004","volume":"146","author":"K Goudy","year":"2013","unstructured":"Goudy K, Aydin D, Barzaghi F, Gambineri E, Vignoli M, Ciullini Mannurita S, Doglioni C, Ponzoni M, Cicalese MP, Assanelli A, et al. Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity. Clin Immunol. 2013;146(3):248\u201361.","journal-title":"Clin Immunol"},{"issue":"4","key":"305_CR10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","volume":"1","author":"A Hartemann","year":"2013","unstructured":"Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, Fonfrede M, Rosenzwajg M, Bernard C, Klatzmann D. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013;1(4):295\u2013305.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"22","key":"305_CR11","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","volume":"365","author":"D Saadoun","year":"2011","unstructured":"Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V, Sene D, Cacoub P, Klatzmann D. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011;365(22):2067\u201377.","journal-title":"N Engl J Med"},{"issue":"9","key":"305_CR12","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/nm.4148","volume":"22","author":"J He","year":"2016","unstructured":"He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, Jin Y, Gan Y, Hu X, Jia R, et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016;22(9):991\u20133.","journal-title":"Nat Med"},{"issue":"7","key":"305_CR13","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","volume":"75","author":"C von Spee-Mayer","year":"2016","unstructured":"von Spee-Mayer C, Siegert E, Abdirama D, Rose A, Klaus A, Alexander T, Enghard P, Sawitzki B, Hiepe F, Radbruch A, et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis. 2016;75(7):1407\u201315.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"305_CR14","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/annrheumdis-2014-206506","volume":"74","author":"JY Humrich","year":"2015","unstructured":"Humrich JY, Von Spee-Mayer C, Siegert E, Alexander T, Hiepe F, Radbruch A, Burmester GR, Riemekasten G. Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. Ann Rheum Dis. 2015;74(4):791\u20132.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"305_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/imm.12351","volume":"144","author":"KW Kim","year":"2015","unstructured":"Kim KW, Chung BH, Kim BM, Cho ML, Yang CW. The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiation in vitro and in vivo in kidney transplant recipients. Immunology. 2015;144(1):68\u201378.","journal-title":"Immunology."},{"issue":"4","key":"305_CR16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.celrep.2012.02.007","volume":"1","author":"Y Kurebayashi","year":"2012","unstructured":"Kurebayashi Y, Nagai S, Ikejiri A, Ohtani M, Ichiyama K, Baba Y, Yamada T, Egami S, Hoshii T, Hirao A, et al. PI3K-Akt-mTORC1-S6K1\/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of ROR\u03b3. Cell Rep. 2012;1(4):360\u201373.","journal-title":"Cell Rep"},{"issue":"2","key":"305_CR17","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.3892\/mmr.2016.5392","volume":"14","author":"L Gu","year":"2016","unstructured":"Gu L, Deng WS, Sun XF, Zhou H, Xu Q. Rapamycin ameliorates CCl4-induced liver fibrosis in mice through reciprocal regulation of the Th17\/Treg cell balance. Mol Med Rep. 2016;14(2):1153\u201361.","journal-title":"Mol Med Rep"},{"key":"305_CR18","unstructured":"Jing X, Gao C, Hao L, Hao M, Liang Z, Li XF, Chen J. Low-dose IL-2 combined with rapamycin efficiently promoted disease remission and recovered the balance of Th17\/regulatory T cells in patients with refractory systemic lupus erythematosus [abstract]. Arthritis Rheumatol. 2018;70(suppl 10)."},{"issue":"9","key":"305_CR19","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"305_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/0961203308094653","volume":"18","author":"JA Reynolds","year":"2009","unstructured":"Reynolds JA, Toescu V, Yee CS, Prabu A, Situnayake D, Gordon C. Effects of rituximab on resistant SLE disease including lung involvement. Lupus. 2009;18(1):67\u201373.","journal-title":"Lupus."},{"issue":"5","key":"305_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1136\/adc.2007.126276","volume":"93","author":"A Podolskaya","year":"2008","unstructured":"Podolskaya A, Stadermann M, Pilkington C, Marks SD, Tullus K. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child. 2008;93(5):401\u20136.","journal-title":"Arch Dis Child"},{"issue":"6","key":"305_CR22","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/art.1780350606","volume":"35","author":"C Bombardier","year":"1992","unstructured":"Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum. 1992;35(6):630\u201340.","journal-title":"Arthritis Rheum"},{"key":"305_CR23","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3389\/fimmu.2015.00493","volume":"6","author":"J Nie","year":"2015","unstructured":"Nie J, Li YY, Zheng SG, Tsun A, Li B. FOXP3(+) Treg cells and gender Bias in autoimmune diseases. Front Immunol. 2015;6:493.","journal-title":"Front Immunol"},{"issue":"1","key":"305_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12865-015-0070-7","volume":"16","author":"A Zickert","year":"2015","unstructured":"Zickert A, Amoudruz P, Sundstr\u00f6m Y, R\u00f6nnelid J, Malmstr\u00f6m V, Gunnarsson I. IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment. BMC Immunol. 2015;16(1):7.","journal-title":"BMC Immunol"},{"issue":"4","key":"305_CR25","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00296-010-1771-0","volume":"32","author":"X Qian","year":"2012","unstructured":"Qian X, Wang B, Cui J, Cui J, Li J. Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis. Rheumatol Int. 2012;32(4):949\u201358.","journal-title":"Rheumatol Int"},{"issue":"6","key":"305_CR26","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.autrev.2013.12.004","volume":"13","author":"M Noack","year":"2014","unstructured":"Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev. 2014;13(6):668\u201377.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"305_CR27","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/art.24499","volume":"60","author":"J Yang","year":"2009","unstructured":"Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X, Wan L, Li M. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009;60(5):1472\u201383.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"305_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.clim.2011.08.005","volume":"141","author":"S Dolff","year":"2011","unstructured":"Dolff S, Bijl M, Huitema MG, Limburg PC, Kallenberg CG, Abdulahad WH. Disturbed Th1, Th2, Th17 and T(reg) balance in patients with systemic lupus erythematosus. Clin Immunol. 2011;141(2):197\u2013204.","journal-title":"Clin Immunol"},{"issue":"4","key":"305_CR29","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.4049\/jimmunol.1201218","volume":"190","author":"G Cheng","year":"2013","unstructured":"Cheng G, Yu A, Dee MJ, Malek TR. IL-2R signaling is essential for functional maturation of T regulatory cells during thymic development. J Immunol. 2013;190(4):1567\u201375.","journal-title":"J Immunol"},{"issue":"9","key":"305_CR30","doi-asserted-by":"publisher","first-page":"e1420","DOI":"10.1038\/cddis.2014.377","volume":"5","author":"D Nazzal","year":"2014","unstructured":"Nazzal D, Gradolatto A, Truffault F, Bismuth J, Berrih-Aknin S. Human thymus medullary epithelial cells promote regulatory T-cell generation by stimulating interleukin-2 production via ICOS ligand. Cell Death Dis. 2014;5(9):e1420.","journal-title":"Cell Death Dis"},{"issue":"6","key":"305_CR31","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.2337\/db14-1322","volume":"64","author":"A Yu","year":"2015","unstructured":"Yu A, Snowhite I, Vendrame F, Rosenzwajg M, Klatzmann D, Pugliese A, Malek TR. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. Diabetes. 2015;64(6):2172\u201383.","journal-title":"Diabetes."},{"key":"305_CR32","doi-asserted-by":"crossref","unstructured":"Villarino A, Laurence A, Robinson GW, Bonelli M, Dema B, Afzali B, Shih HY, Sun HW, Brooks SR, Hennighausen L, et al. Signal transducer and activator of transcription 5 (STAT5) paralog dose governs T cell effector and regulatory functions. Elife. 2016;5.","DOI":"10.7554\/eLife.08384"},{"issue":"2\u20133","key":"305_CR33","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/pmic.201400194","volume":"15","author":"N Osinalde","year":"2015","unstructured":"Osinalde N, Sanchezquiles V, Akimov V, Guerra B, Blagoev B, Kratchmarova I. Simultaneous dissection and comparison of IL-2 and IL-15 signaling pathways by global quantitative phosphoproteomics. Proteomics. 2015;15(2\u20133):520\u201331.","journal-title":"Proteomics."},{"issue":"1","key":"305_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.cmet.2014.05.004","volume":"20","author":"AN Macintyre","year":"2014","unstructured":"Macintyre AN, Gerriets VA, Nichols AG, Michalek RD, Rudolph MC, Deoliveira D, Anderson SM, Abel ED, Chen BJ, Hale LP, et al. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab. 2014;20(1):61\u201372.","journal-title":"Cell Metab"},{"issue":"9","key":"305_CR35","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.4049\/jimmunol.180.9.5794","volume":"180","author":"S Basu","year":"2008","unstructured":"Basu S, Golovina T, Mikheeva T, June CH, Riley JL. Cutting edge: Foxp3-mediated induction of Pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol. 2008;180(9):5794\u20138.","journal-title":"J Immunol"},{"issue":"10","key":"305_CR36","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.4049\/jimmunol.1400044","volume":"193","author":"S Kshirsagar","year":"2014","unstructured":"Kshirsagar S, Riedl M, Billing H, T\u00f6nshoff B, Thangavadivel S, Steuber C, Staude H, Wechselberger G, Edelbauer M. Akt-dependent enhanced migratory capacity of Th17 cells from children with lupus nephritis. J Immunol. 2014;193(10):4895\u2013903.","journal-title":"J Immunol"},{"issue":"12","key":"305_CR37","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1111\/1756-185X.12509","volume":"19","author":"LM Banica","year":"2016","unstructured":"Banica LM, Besliu AN, Pistol GC, Stavaru C, Vlad V, Predeteanu D, Ionescu R, Stefanescu M, Matache C. Dysregulation of anergy-related factors involved in regulatory T cells defects in systemic lupus erythematosus patients: rapamycin and vitamin D efficacy in restoring regulatory T cells. Int J Rheum Dis. 2016;19(12):1294\u2013303.","journal-title":"Int J Rheum Dis"},{"issue":"6483","key":"305_CR38","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/369756a0","volume":"369","author":"EJ Brown","year":"1994","unstructured":"Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994;369(6483):756\u20138.","journal-title":"Nature."}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-019-0305-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12865-019-0305-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-019-0305-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T19:09:27Z","timestamp":1599073767000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-019-0305-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,4]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["305"],"URL":"https:\/\/doi.org\/10.1186\/s12865-019-0305-0","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,4]]},"assertion":[{"value":"25 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All research on humans was performed in accordance to the Declaration of Helsinki. All human subjects read and signed a consent form after being presented with an opportunity to ask questions related to the study. This study was conducted as approved by the Ethics committee, the Second hospital of Shanxi Medical University (The Efficacy and Safety of Low Dose IL-2 Conbined Rapamycin Therapy in Chinese Over-treated Patients with Systemic Lupus Erythematosus, 2016KY-007,2016KY-015).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}